R. Amat

发表

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC

E. Felip, S. Cedrés, A. Navarro, 2022, Journal for ImmunoTherapy of Cancer.

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer

E. Felip, S. Cedrés, A. Navarro, 2022, Frontiers in Medicine.

DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity

Roman K. Thomas, E. Felip, I. Melero, 2022, The Journal of experimental medicine.

Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients

E. Felip, S. Cedrés, A. Navarro, 2021, Cancers.

Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer

E. Felip, S. Cedrés, P. Nuciforo, 2020, Molecular oncology.

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort

E. Felip, S. Cedrés, R. Dienstmann, 2021, Scientific Reports.

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

E. Felip, S. Cedrés, A. Navarro, 2023, Molecular oncology.

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.

E. Ambrosini, A. Pedrocchi, Marcello Restelli, 2023, Clinical lung cancer.

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients

E. Felip, P. Nuciforo, R. Dienstmann, 2023, Cancers.